CJC-1295 and Ipamorelin: What They Are, What the Research Shows, and How to Verify Purity

This blend pairs two molecules that work on the same biological system from different angles, and it carries the single most common labelling ambiguity in the research-peptide market: “CJC-1295” is sold in two forms that are not the same molecule, differ by roughly 280 daltons, and behave very differently. If you read only one section of this article, read the one on DAC. Here is what each compound is, what the published research actually examined – including, unusually for this market, a real human trial – and how to verify a two-peptide vial.

What are these two compounds?

Both relate to growth hormone release, which the body controls through two opposing signals: a releasing signal (GHRH, growth-hormone-releasing hormone) and an inhibiting signal. A third pathway, the ghrelin receptor, also stimulates release. The two compounds in this blend act on two of those routes.

CJC-1295 is a modified analogue of GHRH. Natural GHRH is 44 amino acids long, and its first 29 residues carry the activity. CJC-1295 is based on that 29-residue portion with four amino-acid substitutions that make it resistant to the enzyme that would normally degrade it within minutes.

Ipamorelin is not a GHRH analogue at all. It is a synthetic pentapeptide – five amino acids – that acts at the ghrelin receptor, the same receptor the “hunger hormone” ghrelin uses, which is also a growth-hormone secretagogue receptor. It was described in 1998 as notably selective: in the original characterisation it stimulated growth hormone release without the accompanying rises in other hormones seen with earlier compounds of its class.

Note that Ipamorelin contains non-standard building blocks – Aib (a synthetic amino acid) and two D-form residues, which are mirror images of the naturally occurring L-forms. This is a fully synthetic designed molecule, not a fragment of anything natural.

The DAC distinction (read this before buying anything labelled CJC-1295)

DAC stands for drug affinity complex – a chemical group attached to the peptide that lets it bind reversibly to albumin, the most abundant protein in blood. Bound to albumin, the peptide is shielded from clearance, and its working life extends from minutes to days.

Here is the problem. Two products are sold under the name “CJC-1295”:

• CJC-1295 with DAC – the actual CJC-1295 as described in the published literature, carrying the albumin-binding group. Mass roughly 3,647 daltons.
• “CJC-1295 without DAC” – which is not CJC-1295. Remove the DAC and what remains is the tetrasubstituted GHRH(1-29) peptide, correctly called modified GRF(1-29). Mass roughly 3,368 daltons – about 280 daltons lighter.

These are different substances with different persistence in the body. The published human trial discussed below studied the DAC version. Buying “CJC-1295” without specifying, and without checking the mass on the certificate, means not knowing which of the two is in the vial. This is not a pedantic distinction – it is the difference between the molecule the literature describes and a different, shorter-lived peptide sold under a borrowed name.

What the research has actually examined

This blend is unusual in the catalog: one of its components has genuine published human data.

And the combination? As with other blends in this market, there is no published controlled study of these two compounds administered together. The pairing has a clear pharmacological rationale – two different receptors feeding into the same output – but rationale is not evidence. No published trial characterises the pair.

Worth being precise about what the human trial did and did not show: it measured hormone levels rising and staying up. That is a pharmacodynamic measurement. It is not a demonstration of any clinical benefit, and the compound’s failure to progress to approval in the two decades since is itself informative.

How researchers think they work

CJC-1295 mimics GHRH at the GHRH receptor on the pituitary, prompting growth-hormone release. Its four amino-acid substitutions block the enzymatic cleavage that inactivates natural GHRH, and the DAC group lets it ride on albumin, extending its presence in circulation from minutes to days.

Ipamorelin acts at a different receptor – the ghrelin receptor – which also drives growth-hormone release through a separate signalling route.

The rationale for combining them is that stimulating two independent inputs to the same system may produce a different release pattern than either alone. Growth-hormone release is naturally pulsatile, and both compounds interact with that rhythm rather than overriding it. This mechanism is described in pharmacology; the combined effect is not characterised in published human work.

What is known about safety

• Neither compound is approved in any country, despite both having been described in the literature for around two decades. CJC-1295 reached an early human trial and did not proceed to approval. That trajectory is a relevant fact.
• Ipamorelin has no published controlled human trial. Its selectivity claim rests on animal and in-vitro work from 1998.
• The blend has no safety data at all. No published study examines the two given together.
• This system has known general risks. Growth hormone and IGF-1 signalling is not a free parameter; medicines that manipulate it are prescription-controlled and monitored precisely because sustained changes carry consequences. A compound designed to elevate these markers for days is, by construction, not a trivial intervention. No published research characterises what that means for a person using unapproved research material.
• Mislabelling is a safety issue, not just a commercial one. If DAC and no-DAC material are indistinguishable on the label, the duration of action is unknown to whoever holds the vial.

PeptSelect does not publish preparation or usage guidance for these compounds, or for any peptide. Not as a legal formality – for unapproved compounds without an established human safety profile, there is no such guidance that could responsibly be given.

How to verify what you actually received

This vial demands more of a certificate than most, for two reasons: it contains two peptides, and one of them has a widely confused variant.

• Which CJC variant? The mass-spectrometry result settles it: roughly 3,647 Da for CJC-1295 with DAC, roughly 3,368 Da for modified GRF(1-29). If the certificate does not state which, that is the first question to ask.
• Both identities confirmed. Two declared peptides means two masses to verify – the CJC component and Ipamorelin at roughly 712 Da. Those masses are far apart, so a proper analysis resolves them cleanly.
• The ratio. A total milligram figure does not say how it divides between the two peptides. The split should be stated, not inferred.
• A real chromatogram – two peptides give two main peaks on an HPLC trace, each attributable to a declared component. See reading a chromatogram.
• Net peptide content and batch matching – see net peptide content and batch verification, plus why third-party testing matters.

Every PeptSelect batch is matched to a published third-party certificate in the COA Vault, and the full testing process is documented in How we test.